Navigation Links
CMPI to Host Hill Briefing Tomorrow on Follow-on Biologic Drugs for Media and Congressional Staff With Reps. Eshoo and Rogers
Date:7/14/2009

Event Focused on Ensuring Patient Safety is Top Priority of Follow-on Biologic Legislation Being Debated on Capitol Hill

WASHINGTON, July 14 /PRNewswire-USNewswire/ -- Tomorrow, Wednesday, July 15th, on Capitol Hill, the Center for Medicine in the Public Interest will host a briefing followed by a question-and-answer session for media and Congressional Staff entitled: "A Follow-on Biologics Legislation Update; Congressional Leaders and Medical Experts Discuss Patient Safety." The event will be co-hosted by two high-ranking members of the House Energy and Commerce Committee, Congresswoman Anna Eshoo (D-CA) and Congressman Mike Rogers (R-MI). The Representatives are lead sponsors of bipartisan legislation to modernize the regulatory pathway for Food and Drug Association approval of follow-on biologics.

Representative Eshoo's legislation: H.R. 1548, the Pathway for Biosimilars Act ensures that new standards for testing will make certain that follow-on biologic drugs are both safe and effective. The bill currently has 108 cosponsors and has the broadest bipartisan support of any legislation designed to regulate follow-on biologics.

"CMPI applauds Representatives Eshoo's and Rogers' commitment to ensuring patient safety is the top-priority for follow-on biologics legislation," said Robert Goldberg of CMPI. "The next few weeks are going to be a pivotal time in Congress as health care takes top billing in the House and the Senate. It is critical that advocates for safe and effective follow-on biologics do all they can to support Representative Eshoo's legislation. Representatives Eshoo's and Rogers' dedication to ensuring FDA takes the appropriate steps to ensure the safety of patients could mean the difference between health and illness for millions of Americans."

Also speaking at the event will be former Congressman Mike Ferguson; Dr. Geno Merli, Senior Vice President & Chief Medical Officer, Thomas Jefferson University, and Director, Jefferson Center for Vascular Diseases; and John F. Crowley, President and Chief Executive Officer of Amicus Therapeutics. All three will help highlight the importance of balancing cost reduction and the well-being of patients in the follow-on biologics debate, bringing their unique experiences and perspectives directly to Hill staffers.

    WHO: Representative Anna Eshoo (D-CA), Representative Mike Rogers (R-MI),
    Leading Medical Experts

    WHAT: Briefing for media and Congressional staff

    WHEN: Tomorrow, Wednesday, July 15th, 12-1 p.m.

    WHERE: Cannon Caucus Room, Cannon House Office Building 3rd Floor,
    Washington, D.C.

    WHY: A Follow-On Biologics Legislation Update; Congressional Leaders
    and Medical Experts Discuss Patient Safety

Those interested in attending this event can RSVP via email to Meryl Reichbach at mreichbach@cmpi.org or by calling her at 212-417-9169.

About CMPI

The Center for Medicine in the Public Interest, a non-profit public policy group dedicated to research-based free market reforms for the health care industry.


'/>"/>
SOURCE CMPI
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Americans Wary of Health Legislation: University of Texas/Zogby Poll to be Released on July 15 -- National Press Club to Host "NEWSMAKER" Media Briefing
2. CMPI to Host Hill Briefing on Follow-On Biologic Drugs for Media and Congressional Staff with Reps. Eshoo and Rogers
3. Actuaries Provide Capitol Hill Briefing to Explore Health Care Reform Components
4. AAHSA Expert To Speak To Help Committee Briefing on Health Care Reform and Long-Term Services and Support
5. U.S. Civil Rights Commission to Hold Public Briefing on Health Care Disparities Between Minorities and Non-Minorities, and Business Meeting
6. Advanced Life Sciences Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on Restanza(TM) (cethromycin)
7. NPC Newsmaker Program Hosts Briefing on Health Care Reform with Former HHS Secretary Michael Leavitt and Former Senate Majority Leader Tom Daschle
8. Mayo study finds that team preop briefing improves communication, reduces errors
9. Mayo Study Finds That Team Preop Briefing Improves Communication, Reduces Errors
10. Mosaica Partners Briefing Paper Identifies Leading Practices for States and Regions to Leverage ARRA Stimulus Funds for HIE
11. National Press Club to Host NEWSMAKER Media Briefing on Cancer Policy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, ... ... health care world, this installment is bolstered by inspiring human interest stories, courtesy ... to the developing trends and tech within the industry, from leading advocates and ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... ... trusted name in the pharmaceutical, medical and food industries. Aside from its GMP ... certification (SIC), providing proof of successfully certified products, services and staff. , Validation ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... W.S. ... products, has been honored with a 2016 When Work Works Award for its use ... part of the national When Work Works project administered by the Families and Work ...
(Date:5/26/2016)... ... 2016 , ... Georgia State University College of Law is ... Answering to the increasing demand for curricular specializations, the Certificate in Intellectual Property ... land use law. ,  , “The demand for lawyers with specific knowledge in ...
(Date:5/26/2016)... , ... May 26, 2016 , ... The Woodlands ... offering a new model of care for living and healing, celebrated its grand ... Meaningful Life in a Real Home provided by Empowered Staff. , “This is an ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
(Date:5/24/2016)... , May 24, 2016 ... the world , s first dual therapy ... intervention   OrbusNeich, a global company specializing ... its portfolio to include products to treat peripheral artery ... company,s first entry devices for lower limb and arteriovenous ...
(Date:5/24/2016)... HONG KONG , May 24, 2016 ... de COMBO ™ , la ... présentent des cathéters destinés à l,intervention portant ... artério-veineuse (FAV)   OrbusNeich, entreprise ... vasculaires permettant de changer la vie, a ...
Breaking Medicine Technology: